Sex Hormones

Sex Hormones Market Outlook

The global sex hormones market is projected to reach approximately USD 52 billion by 2035, growing at a CAGR of about 6.5% during the forecast period from 2025 to 2035. This growth can be attributed to several factors, including an increase in the prevalence of hormonal disorders, the rising awareness of hormone replacement therapies, and a growing aging population that requires various hormonal treatments. Additionally, advancements in biotechnology and pharmaceutical research have spurred the development of innovative sex hormone therapies tailored to meet the specific needs of patients. The surge in healthcare expenditure across emerging economies is also expected to bolster market growth, facilitating broader access to hormonal therapies. The increasing acceptance and recognition of transgender rights have further propelled the demand for sex hormones, especially in gender affirmation processes, thereby expanding the market landscape significantly.

Growth Factor of the Market

One of the primary growth factors for the sex hormones market is the increasing prevalence of hormonal imbalances, particularly among the aging population. Conditions such as menopause in women and low testosterone levels in men contribute significantly to the demand for hormonal therapies. Additionally, the growing awareness regarding hormone replacement therapy (HRT) and its benefits is driving more individuals to seek medical advice and treatment. The trend toward personalized medicine, focusing on individual hormonal needs, is also gaining traction, leading to the development of tailored therapies that cater specifically to patient requirements. Furthermore, the rise in infertility rates worldwide has created a significant need for hormonal treatments, such as estrogen and progesterone, in assisted reproductive technologies. The acceptance and support of transgender individuals in society have opened new avenues for the market, requiring specific hormone therapies for gender affirmation.

Key Highlights of the Market

• The global sex hormones market is expected to reach USD 52 billion by 2035.
• The market is projected to grow at a CAGR of 6.5% from 2025 to 2035.
• Increasing prevalence of hormonal disorders among aging populations is a significant driver.
• The growing awareness of hormone replacement therapies contributes to market expansion.
• Rising acceptance of transgender rights has led to increased demand for gender affirmation hormone therapies.

By Type

Testosterone:

Testosterone, the primary male sex hormone, plays a crucial role in the development of male reproductive tissues and the promotion of secondary sexual characteristics. The testosterone segment is experiencing significant growth largely due to the rising incidence of testosterone deficiency in men, commonly referred to as androgen deficiency. This has led to an increased focus on testosterone replacement therapies (TRT) to alleviate symptoms such as fatigue, decreased libido, and mood changes. Moreover, the growing trend of fitness and bodybuilding among men has spurred interest in testosterone therapies, resulting in a heightened demand for both prescription and over-the-counter testosterone boosters. Additionally, the acceptance of TRT by healthcare professionals has led to more men seeking treatment, thereby reinforcing the testosterone segment’s market position.

Estrogen:

Estrogen, the primary female sex hormone, is vital for various bodily functions, including the regulation of the menstrual cycle and the development of female secondary sexual characteristics. The estrogen segment is notably driven by the increasing prevalence of menopause-related symptoms among women, which often leads to the adoption of hormone replacement therapy (HRT) to manage these symptoms effectively. Furthermore, estrogen plays a crucial role in reproductive health, making it essential for various infertility treatments, thus contributing to its market demand. The rise in awareness regarding the health risks associated with menopause, such as osteoporosis and cardiovascular diseases, has prompted women to seek estrogen therapies more actively. As a result, the estrogen segment is expected to witness substantial growth, fueled by increased marketing efforts and education around HRT.

Progesterone:

Progesterone is another vital sex hormone, primarily involved in regulating the menstrual cycle and supporting pregnancy. The demand for progesterone is significantly influenced by its application in hormone replacement therapy, particularly for women during menopause and for those undergoing assisted reproductive technologies (ART). The growing trend of women opting for fertility treatments has positively impacted the progesterone segment, as it is often used to prepare the endometrium for embryo implantation. Additionally, the increasing awareness of progesterone’s role in managing various gynecological conditions, such as endometriosis and irregular menstruation, has spurred its market growth. With numerous clinical studies supporting the benefits of progesterone therapy, the segment is poised for growth, particularly in fertility and reproductive health applications.

Follicle-Stimulating Hormone:

Follicle-stimulating hormone (FSH) is crucial for reproductive processes in both males and females, stimulating the growth of ovarian follicles in women and supporting spermatogenesis in men. The market for FSH is primarily driven by rising infertility rates and an increasing number of women seeking fertility treatments. FSH is a key component of in vitro fertilization (IVF) protocols, making it indispensable in assisted reproductive technologies. As more couples turn to IVF due to factors such as advanced maternal age and lifestyle choices, the demand for FSH has surged. Additionally, ongoing advancements in biotechnology are leading to the development of more effective and cost-efficient FSH formulations, further enhancing market growth prospects in this segment.

Luteinizing Hormone:

Luteinizing hormone (LH) plays a significant role in regulating the menstrual cycle and ovulation in women and is involved in testosterone production in men. The segment for LH is influenced by its essential functions in reproductive health, particularly in fertility treatments. As awareness about fertility options grows, the demand for LH in conjunction with other hormones like FSH in ART practices is on the rise. Moreover, LH testing kits are becoming increasingly popular among couples trying to conceive, bolstering demand in both clinical and home testing scenarios. The dual role of LH in both male and female reproductive health underscores its importance, leading to expanded applications in medical treatments and diagnostics related to hormonal imbalances.

By Application

Hormone Replacement Therapy:

The hormone replacement therapy (HRT) segment is a significant driver of the sex hormones market, particularly for menopausal women seeking to alleviate symptoms such as hot flashes, night sweats, and mood swings. HRT typically includes a combination of estrogen and progesterone, and its acceptance is growing as more women become aware of the potential benefits and risks associated with hormonal treatments. Additionally, HRT has been shown to play a critical role in preventing osteoporosis and cardiovascular diseases, which are prevalent among postmenopausal women. The rise in public awareness campaigns promoting HRT and its advantages is expected to further drive this segment’s growth, along with an increasing number of healthcare providers advocating for the safe use of hormones in managing menopausal symptoms.

Contraception:

The contraception segment remains a significant contributor to the sex hormones market, with various hormonal contraceptive options available, including oral contraceptive pills, patches, and injections. Hormonal contraceptives, primarily containing estrogen and progesterone, offer effective prevention of unintended pregnancies while providing additional health benefits, such as regulating menstrual cycles and reducing the risk of certain reproductive health issues. The growing acceptance of family planning and reproductive rights, particularly among younger populations, has led to a surge in contraceptive use. Moreover, the increased focus on educating individuals about contraception options and their potential health benefits is likely to enhance market growth in this segment, as more people seek reliable contraceptive methods tailored to their lifestyles.

Infertility Treatment:

This segment has gained significant traction due to rising infertility rates worldwide, driven by factors such as lifestyle changes, advanced maternal age, and environmental influences. Infertility treatments often utilize sex hormones, including estrogen and progesterone, to support assisted reproductive technologies like IVF and intrauterine insemination (IUI). The increasing number of couples seeking fertility treatments has resulted in a robust market for infertility therapies, with healthcare providers offering comprehensive services that include hormonal evaluations and personalized treatment plans. The rising awareness regarding reproductive health and growing access to fertility clinics are expected to further promote growth in this segment, as more individuals turn to medical assistance for conception-related challenges.

Gender Affirmation:

Gender affirmation therapy has emerged as a crucial application of sex hormones, especially as societal acceptance and support for transgender individuals have increased. Hormones such as estrogen and testosterone are widely used to align an individual's physical characteristics with their gender identity. As more people seek out gender-affirming treatments, the demand for sex hormones in this application is surging. The availability of specialized clinics and healthcare providers offering tailored hormone regimens has made it easier for individuals to access these essential therapies. Furthermore, the growing advocacy for transgender rights and improved healthcare policies are expected to bolster market growth in this segment, providing more individuals with the necessary support for their gender affirmation journey.

By Distribution Channel

Hospitals & Clinics:

The hospitals and clinics segment remains a critical distribution channel for sex hormones, as they provide comprehensive healthcare services, including diagnosis and treatment for hormonal disorders. Patients often prefer receiving their hormonal therapies from qualified healthcare professionals who can offer personalized treatment plans and monitor their progress effectively. Hospitals and clinics are equipped with the necessary facilities to conduct comprehensive evaluations and blood tests, ensuring that patients receive the right dosage and type of hormones. The growing emphasis on patient safety and the importance of regular medical supervision are key factors driving the demand for sex hormones through this channel. As healthcare systems continue to evolve, this segment will likely capture a significant share of the market due to its trusted reputation and holistic approach to patient care.

Retail Pharmacies:

Retail pharmacies play a substantial role in the distribution of sex hormones, particularly for patients seeking convenience and accessibility. Many individuals prefer purchasing their medications from local pharmacies due to the ease of access, especially for ongoing hormone therapies. Retail pharmacies often offer a wide range of hormonal products, including oral contraceptives and hormone replacement therapies, making them a go-to source for many patients. The increasing number of retail pharmacy chains and the availability of trained pharmacists who can provide valuable information and support further enhance this distribution channel. Additionally, the trend toward self-medication and the growing demand for over-the-counter hormone supplements have positioned retail pharmacies as a vital player in the sex hormones market.

Online Pharmacies:

The rise of online pharmacies has transformed the distribution landscape for sex hormones, offering convenience and privacy to consumers. The ability to order medications from the comfort of one's home has become increasingly appealing, particularly for individuals seeking hormone therapies who may prefer discretion. Online pharmacies often provide a wide selection of products and competitive pricing, making them an attractive option for consumers. The ongoing digital transformation in healthcare has led to improved online platforms, enabling consumers to have their prescriptions filled quickly and securely. Additionally, the growing acceptance of telemedicine and online consultations allows patients to access healthcare professionals easily, further driving the demand for sex hormones through this distribution channel. As technology continues to advance, the online pharmacy segment is poised for considerable growth.

By End User

Men:

The male segment is a significant portion of the sex hormones market, primarily driven by the increasing prevalence of testosterone deficiency and its associated health concerns. As men age, testosterone levels naturally decline, leading to various physical and psychological symptoms, including fatigue, decreased libido, and mood changes. This has resulted in a growing awareness and acceptance of testosterone replacement therapy (TRT) among men seeking to enhance their quality of life. The stigma surrounding hormone treatments for men is gradually diminishing, as more individuals recognize the benefits of addressing hormonal imbalances. Consequently, the demand for testosterone therapies is expected to rise, with increasing numbers of healthcare providers offering specialized services tailored to men's health needs.

Women:

The female segment constitutes a significant share of the sex hormones market, driven predominantly by the challenges associated with menopause and hormonal disorders. Women experiencing menopause often seek hormone replacement therapy (HRT) to alleviate symptoms such as hot flashes, night sweats, and mood swings. The rising awareness regarding the health implications of menopause, including the risk of osteoporosis and cardiovascular diseases, has led many women to explore HRT options actively. Additionally, hormonal treatments for conditions like polycystic ovary syndrome (PCOS) and endometriosis are gaining traction, further driving the demand for sex hormones among women. The healthcare industry’s increasing focus on women's health issues indicates a promising outlook for this segment, as more women seek solutions for managing their hormonal health.

Transgender Individuals:

The segment of transgender individuals represents an important aspect of the sex hormones market, primarily driven by the demand for gender affirmation therapies. Hormones such as estrogen and testosterone are utilized to help align an individual’s physical traits with their gender identity, playing a crucial role in the transition process. As societal acceptance of transgender rights continues to grow, more individuals are seeking access to hormone therapies, leading to a significant increase in demand. The availability of specialized clinics and healthcare providers offering tailored hormone regimens has made it easier for transgender individuals to find the support they need. Furthermore, advocacy for comprehensive healthcare coverage for gender-affirming treatments is expected to enhance access and affordability, significantly contributing to the growth of this market segment.

By Region

North America holds a dominant position in the sex hormones market, primarily due to the high prevalence of hormonal disorders, extensive healthcare infrastructure, and increasing awareness regarding hormone replacement therapies. The market in North America is projected to grow at a CAGR of approximately 6.8% during the forecast period, driven by technological advancements and a broad range of treatment options available to patients. The presence of key industry players and continuous research and development efforts further enhance market prospects in this region. The growing acceptance of hormone therapies, particularly among aging populations and transgender individuals, is anticipated to create significant opportunities for market expansion in North America, solidifying its leadership status in the global landscape.

Europe is another key region contributing to the sex hormones market, characterized by a growing aging population and increasing healthcare expenditures. The European market is expected to witness steady growth, with an emphasis on hormone replacement therapies for menopausal women and infertility treatments. Various initiatives aimed at raising awareness regarding reproductive health and hormonal therapies are expected to drive market demand. Additionally, countries with advanced healthcare systems, such as Germany, France, and the UK, are likely to experience higher adoption rates of sex hormones, particularly in the context of hormone replacement and infertility treatments. The combined efforts of healthcare providers and policymakers to improve access to hormonal therapies are expected to further promote market growth in Europe.

Opportunities

The sex hormones market is poised for significant opportunities, particularly in the realm of personalized medicine. Advances in genomics and biotechnology are paving the way for tailored hormone therapies that cater to the unique biological needs of individual patients. This shift toward personalized treatments can enhance patient compliance and improve health outcomes by ensuring that the hormone therapies administered are specifically designed for the individual's hormonal profile. Additionally, the increasing acceptance and understanding of transgender health needs present a unique opportunity for pharmaceutical companies to develop specialized hormone therapies that align with the specific requirements of transgender individuals. As society continues to embrace diversity in gender identity, the demand for effective gender-affirming treatments is expected to soar, reinforcing the need for innovative therapeutic solutions.

Another significant opportunity lies in expanding access to sex hormones in emerging markets. As healthcare infrastructure improves and awareness of hormonal health grows, countries in Asia Pacific and Latin America are likely to experience a surge in demand for hormone therapies. Increasing incomes, coupled with a rising focus on reproductive health, provide an excellent backdrop for market expansion in these regions. Additionally, collaborations between local healthcare providers and international pharmaceutical companies can facilitate the introduction of advanced hormonal therapies, thereby enhancing patient access and treatment options. As the global landscape evolves, tapping into these emerging markets will be crucial for companies looking to capitalize on the growing sex hormones market.

Threats

Despite the promising growth prospects, the sex hormones market faces various threats that could impede its expansion. Regulatory challenges pose a significant hurdle, as the approval process for new hormonal therapies can be lengthy and complex, resulting in delays in bringing innovative products to market. Additionally, the evolving landscape of healthcare policy and insurance coverage may impact patient access to hormone therapies, particularly in regions where there is resistance to hormonal treatments. The threat of counterfeit medications further complicates the market, as consumers may unknowingly purchase substandard or ineffective products, potentially leading to adverse health outcomes. As a result, the integrity of the supply chain and the need for stringent quality control measures will be paramount to ensure patient safety and trust in hormonal therapies.

Moreover, social stigma surrounding hormone therapy, particularly among men using testosterone for low testosterone levels, can deter individuals from seeking treatment. This stigma may contribute to lower diagnosis rates and delay individuals from pursuing necessary medical advice regarding hormonal imbalances. Additionally, public misconceptions about hormone treatments can further exacerbate this challenge, leading to hesitancy in the adoption of therapies. Addressing these societal perceptions through education and awareness campaigns will be crucial in mitigating these threats and promoting a more informed understanding of hormone therapies.

Competitor Outlook

• Pfizer Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Amgen Inc.
• HRA Pharma
• Ferring Pharmaceuticals
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Endo Pharmaceuticals Inc.
• Helsinn Healthcare SA
• Akorn Operating Company LLC
• Mylan N.V.
• Allergan PLC

The competitive landscape of the sex hormones market is characterized by the presence of numerous global and regional players who are continuously innovating and broadening their product portfolios to maintain a competitive edge. Major pharmaceutical companies are investing significantly in research and development, focusing on the creation of advanced hormonal therapies that cater to the evolving needs of patients. Collaborations and partnerships between companies are also becoming increasingly common, as firms seek to leverage each other's strengths and expertise to enhance their offerings. This competitive environment is further intensified by the entry of new players, particularly in emerging markets, which is expected to reshape the market dynamics significantly.

Key industry players, such as Pfizer Inc. and AbbVie Inc., have established themselves as leaders in the sex hormones market by offering a wide range of hormone therapies, particularly in the areas of hormone replacement therapy and infertility treatments. Pfizer Inc. has a robust portfolio that includes therapies for testosterone replacement, contributing to its strong position in the male hormonal health segment. AbbVie Inc., on the other hand, focuses on developing innovative therapies for both men and women, emphasizing its commitment to addressing various hormonal disorders. Their continued investment in clinical research and collaborations with healthcare professionals further supports their growth in this competitive market.

Another significant player, Merck & Co., Inc., is recognized for its comprehensive approach to hormone therapies, offering a range of products targeting estrogen and progesterone deficiencies. The company’s emphasis on education and support for healthcare providers plays a vital role in increasing awareness and adoption of its therapies. Additionally, companies like Teva Pharmaceutical Industries Ltd. and Novartis AG are focusing on producing generic and branded hormone therapies, ensuring that a wide range of treatment options are accessible to patients. The competition is expected to intensify as these companies expand their product lines and explore global markets, particularly in regions with increasing demand for hormone therapies.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 HRA Pharma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Mylan N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Allergan PLC
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Helsinn Healthcare SA
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Ferring Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim GmbH
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Endo Pharmaceuticals Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Akorn Operating Company LLC
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Sex Hormones Market, By Type
    • 6.1.1 Testosterone
    • 6.1.2 Estrogen
    • 6.1.3 Progesterone
    • 6.1.4 Follicle-Stimulating Hormone
    • 6.1.5 Luteinizing Hormone
  • 6.2 Sex Hormones Market, By End User
    • 6.2.1 Men
    • 6.2.2 Women
    • 6.2.3 Transgender Individuals
  • 6.3 Sex Hormones Market, By Application
    • 6.3.1 Hormone Replacement Therapy
    • 6.3.2 Contraception
    • 6.3.3 Infertility Treatment
    • 6.3.4 Gender Affirmation
  • 6.4 Sex Hormones Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Sex Hormones Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Sex Hormones market is categorized based on

By Type

• Testosterone
• Estrogen
• Progesterone
• Follicle-Stimulating Hormone
• Luteinizing Hormone

By Application

• Hormone Replacement Therapy
• Contraception
• Infertility Treatment
• Gender Affirmation

By Distribution Channel

• Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies

By End User

• Men
• Women
• Transgender Individuals

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Amgen Inc.
• HRA Pharma
• Ferring Pharmaceuticals
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Endo Pharmaceuticals Inc.
• Helsinn Healthcare SA
• Akorn Operating Company LLC
• Mylan N.V.
• Allergan PLC